Endothelin and hepatic wound healing

Pharmacological Research

Volumn 63, Issue 6, 2011, Pages 512-518

  Khimji, Al Karim ^a   Rockey, Don C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Liver

Indexed keywords

27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; ALPHA SMOOTH MUSCLE ACTIN; AMBRISENTAN; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MATRIX PROTEIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SITAXSENTAN;

BRAIN ISCHEMIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEEDBACK SYSTEM; HEART FAILURE; HUMAN; LIVER CIRRHOSIS; LIVER INJURY; LIVER REGENERATION; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; STELLATE CELL; WOUND HEALING;

ENDOTHELIN-1; HEPATIC STELLATE CELLS; HUMANS; LIVER; LIVER DISEASES; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 79958049143     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.03.005     Document Type: Review

References (124)

1. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985;82:8681-5. (Pubitemid 16101107)
2. Rockey DC, Friedman SL. Cytoskeleton of liver perisinusoidal cells (lipocytes) in normal and pathological conditions. Cell Motil Cytoskeleton 1992;22:227-34.
3. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992;24:193-203.
4. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990;86:1641-8. (Pubitemid 20372615)
5. Bissell DM, Friedman SL, Maher JJ, Roll FJ. Connective tissue biology and hepatic fibrosis: report of a conference. Hepatology 1990;11:488-98. (Pubitemid 20120005)
6. Desmouliere A. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int 1995;19:471-6.
7. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-8.
8. Asbert M, Gines A, Gines P, Jimenez W, Claria J, Salo J, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993;104:1485-91. (Pubitemid 23235424)
9. Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998;27:472-80. (Pubitemid 28081062)
10. Ota T, Hirai R, Urakami A, Soga H, Nawa S, Shimizu N. Endothelin-1 levels in portal venous blood in relation to hepatic tissue microcirculation disturbance and hepatic cell injury after ischemia/reperfusion. Surg Today 1997;27:313-20. (Pubitemid 27164191)
11. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5. (Pubitemid 18090241)
12. Elshourbagy NA, Korman DR, Wu HL, Sylvester DR, Lee JA, Nuthalaganti P, et al. Molecular characterization and regulation of the human endothelin receptors. J Biol Chem 1993;268:3873-9. (Pubitemid 23072916)
13. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003;81:607-21. (Pubitemid 36836395)
14. Wanecek M, Weitzberg E, Rudehill A, Oldner A. The endothelin system in septic and endotoxin shock. Eur J Pharmacol 2000;407:1-15.
15. Lee ME, Bloch KD, Clifford JA, Quertermous T. Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem 1990;265:10446-50.
16. Lee ME, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T. Regulation of endothelin-1 gene expression by fos and jun. J Biol Chem 1991;266:19034-9. (Pubitemid 21908188)
17. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear factor-kappab in age-stimulated cultured endothelial cells. Diabetes 2000;49:1561-70.
18. Yoshimura H, Nishimura J, Sakihara C, Kobayashi S, Takahashi S, Kanaide H. Expression and function of endothelins, endothelin receptors, and endothelin converting enzyme in the porcine trachea. Am J Respir Cell Mol Biol 1997;17:471-80. (Pubitemid 127500980)
19. Xavier FE, Yogi A, Callera GE, Tostes RC, Alvarez Y, Salaices M, et al. Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain. Br J Pharmacol 2004;143:794-802. (Pubitemid 39611615)
20. Yanagisawa M, Inoue A, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. J Cardiovasc Pharmacol 1989;13(Suppl. 5):S13-17, discussion S18.
21. Macours N, Poels J, Hens K, Francis C, Huybrechts R. Structure, evolutionary conservation, and functions of angiotensin- and endothelin-converting enzymes. Int Rev Cytol 2004;239:47-97. (Pubitemid 39349483)
22. Ohnaka K, Takayanagi R, Nishikawa M, Haji M, Nawata H. Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. Off J Biol Chem 1993;268:26759-66. (Pubitemid 23361765)
23. Turner AJ, Murphy LJ. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 1996;51:91-102. (Pubitemid 26020684)
24. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85.
25. D'Orleans-Juste P, Plante M, Honore JC, Carrier E, Labonte J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003;81:503-10. (Pubitemid 36836386)
26. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme (ece-1). J Biol Chem 1995;270:29794-8. (Pubitemid 26001648)
27. Schmidt M, Kroger B, Jacob E, Seulberger H, Subkowski T, Otter R, et al. Molecular characterization of human and bovine endothelin converting enzyme (ece-1). FEBS Lett 1994;356:238-43. (Pubitemid 24376980)
28. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic ph optimum. J Biol Chem 1995;270:15262-8.
29. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-76. (Pubitemid 32385909)
30. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, et al. Disruption of ece-1 and ece-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000;105:1373-82. (Pubitemid 30322403)
31. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997;159:1987-92. (Pubitemid 127484189)
32. Simonson MS, Dunn MJ. Cellular signaling by peptides of the endothelin gene family. Faseb J 1990;4:2989-3000. (Pubitemid 120012545)
33. Masaki T. Historical review: endothelin. Trends Pharmacol Sci 2004;25:219-24. (Pubitemid 38519913)
34. Clozel M, Gray GA. Are there different etb receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995;26(Suppl. 3):S262-264.
35. Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis ofwoundhealing. J Clin Invest 1996;98:1381-8. (Pubitemid 26322063)
36. Battistini B, Warner TD, Fournier A, Vane JR. Characterization of etb receptors mediating contractions induced by endothelin-1 or irl 1620 in guinea-pig isolated airways: effects of bq-123, fr139317 or pd 145065. Br J Pharmacol 1994;111:1009-16. (Pubitemid 2057477)
37. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (etc receptor) from xenopus laevis dermal melanophores. J Biol Chem 1993;268:19126-33. (Pubitemid 23273869)
38. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a rho-associated protein kinase in hypertension. Nature 1997;389:990-4. (Pubitemid 27485693)
39. Moller S, Henriksen JH. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. Ugeskr Laeger 1993;155:728-9.
40. Trevisani F, Colantoni A, Gerbes AL, Gulberg V, Sica G, Caraceni P, et al. Daily profile of plasma endothelin-1 and -3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal function. J Hepatol 1997;26:808-15. (Pubitemid 27145703)
41. Alam I, Bass NM, Bacchetti P, Gee L, Rockey DC. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol 2000;95:199-203. (Pubitemid 30041559)
42. Feng HQ, Weymouth ND, Rockey DC. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol 2009;297:G27-33.
43. Thirunavukkarasu C, Yang Y, Subbotin VM, Harvey SA, Fung J, Gandhi CR. Endothelin receptor antagonist tak-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats. Gut 2004;53:1010-9. (Pubitemid 38824161)
44. Cavasin MA, Semus H, Pitts K, Peng Y, Sandoval J, Chapo J, et al. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats. Can J Physiol Pharmacol 2010;88:636-43.
45. Shao R, Shi Z, Gotwals PJ, Koteliansky VE, George J, Rockey DC. Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Mol Biol Cell 2003;14:2327-41. (Pubitemid 36724324)
46. Shao R, Rockey DC. Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing. J Cell Physiol 2002;191:342-50. (Pubitemid 34462485)
47. Zhan S, Chan CC, Serdar B, Rockey DC. Fibronectin stimulates endothelin-1 synthesis in rat hepatic myofibroblasts via a src/erk-regulated signaling pathway. Gastroenterology 2009;136:2345-55, e2341-2344.
48. Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci USA 1993;90:9266-70. (Pubitemid 23315764)
49. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416. (Pubitemid 32923768)
50. Schuppan D, Popov Y. Hepatic fibrosis: from bench to bedside. J Gastroenterol Hepatol 2002;17(Suppl 3):S300-305.
51. Gabriel A, Kuddus RH, Rao AS, Gandhi CR. Down-regulation of endothelin receptors by transforming growth factor beta1 in hepatic stellate cells. J Hepatol 1999;30:440-50. (Pubitemid 29113233)
52. Chi X, Anselmi K, Watkins S, Gandhi CR. Prevention of cultured rat stellate cell transformation and endothelin-b receptor upregulation by retinoic acid. Br J Pharmacol 2003;139:765-74. (Pubitemid 36819604)
53. Gandhi CR, Kuddus RH, Nemoto EM, Murase N. Endotoxin treatment causes an upregulation of the endothelin system in the liver: amelioration of increased portal resistance by endothelin receptor antagonism. J Gastroenterol Hepatol 2001;16:61-9. (Pubitemid 32120936)
54. Schmitt-Graff A, Kruger S, Bochard F, Gabbiani G, Denk H. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991;138:1233-42.
55. Khimji AK, Rockey DC. Endothelin-biology and disease. Cell Signal 2010;22:1615-25.
56. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-72.
57. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69. (Pubitemid 351615417)
58. Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. Faseb J 1991;5:271-7. (Pubitemid 21892886)
59. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50. (Pubitemid 30081976)
60. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-81. (Pubitemid 34638880)
61. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998;18:2-13. (Pubitemid 28127751)
62. Yata Y, Gotwals P, Koteliansky V, Rockey DC. Dose-dependent inhibition of hepatic fibrosis in mice by a tgf-beta soluble receptor: implications for antifibrotic therapy. Hepatology 2002;35:1022-30. (Pubitemid 34453999)
63. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. (Pubitemid 40385459)
64. Khimji AK, Shao R, Rockey DC. Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ece-1 regulation. Am J Pathol 2008;173:716-27.
65. Yang SN, Burch ML, Tannock LR, Evanko S, Osman N, Little PJ. Transforming growth factor-beta regulation of proteoglycan synthesis in vascular smooth muscle: contribution to lipid binding and accelerated atherosclerosis in diabetes. J Diabetes 2010;2:233-42.
66. Koda M, Bauer M, Krebs A, Hahn EG, Schuppan D, Murawaki Y. Endothelin-1 enhances fibrogenic gene expression, but does not promote DNA synthesis or apoptosis in hepatic stellate cells. Comp Hepatol 2006;5:5.
67. Shephard P, Hinz B, Smola-Hess S, Meister JJ, Krieg T, Smola H. Dissecting the roles of endothelin, tgf-beta and gm-csf on myofibroblast differentiation by keratinocytes. Thromb Haemost 2004;92:262-74. (Pubitemid 39172306)
68. Shephard P, Martin G, Smola-Hess S, Brunner G, Krieg T, Smola H. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 2004;164:2055-66. (Pubitemid 38669353)
69. Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, et al. Anti-pdgfb monoclonal antibody reduces liver fibrosis development. Hepatol Res 2010;40:1128-41.
70. Kinnman N, Goria O, Wendum D, Gendron MC, Rey C, Poupon R, et al. Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest 2001;81:1709-16. (Pubitemid 33144433)
71. Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, et al. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing pdgf/tgf-beta signaling in hepatic stellate cells. J Clin Invest 2010;120:2379-94.
72. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989;257:H2033-2035.
73. Clerk A, Sugden PH. Regulation of phospholipases c and d in rat ventricular myocytes: stimulation by endothelin-1, bradykinin and phenylephrine. J Mol Cell Cardiol 1997;29:1593-604. (Pubitemid 27270230)
74. Pfitzer G. Invited review: regulation of myosin phosphorylation in smooth muscle. J Appl Physiol 2001;91:497-503. (Pubitemid 32574761)
75. Stull JT, Lin PJ, Krueger JK, Trewhella J, Zhi G. Myosin light chain kinase: functional domains and structural motifs. Acta Physiol Scand 1998;164:471-82. (Pubitemid 29015666)
76. Shimizu I, Mizobuchi Y, Yasuda M, Shiba M, Ma YR, Horie T, et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999;44:127-36. (Pubitemid 29143293)
77. Laleman W, Van Landeghem L, Severi T, Vander Elst I, Zeegers M, Bisschops R, et al. Both ca2+-dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007;292:G556-564.
78. Reinehr R, Sommerfeld A, Haussinger D. Cd95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 2008;134:1494-506.
79. Muranyi A, MacDonald JA, Deng JT, Wilson DP, Haystead TA, Walsh MP, et al. Phosphorylation of the myosin phosphatase target subunit by integrin-linked kinase. Biochem J 2002;366:211-6. (Pubitemid 34971820)
80. Shafiei MS, Rockey DC. The role of integrin-linked kinase in liver wound healing. J Biol Chem 2006;281:24863-72. (Pubitemid 44274258)
81. 2+ sensitization via myosin phosphatase inhibition. J Biol Chem 2002;277:23441-6.
82. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, et al. Endothelin-a receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994;370:301-4. (Pubitemid 24250126)
83. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000;269:652-9. (Pubitemid 30440356)
84. Perri RE, Langer DA, Chatterjee S, Gibbons SJ, Gadgil J, Cao S, et al. Defects in cgmp-pkg pathway contribute to impaired no-dependent responses in hepatic stellate cells upon activation. Am J Physiol Gastrointest Liver Physiol 2006;290:G535-542.
85. Rockey DC, Housset CN, Friedman SL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993;92:1795-804. (Pubitemid 23304545)
86. Wake K. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin a-storing cells in extrahepatic organs. Int Rev Cytol 1980;66:303-53.
87. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999;19:359-82. (Pubitemid 30032639)
88. McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver 2000;20:3-7. (Pubitemid 30095282)
89. Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: in vivo methodology and control by endothelins. Semin Liver Dis 1999;19:383-96. (Pubitemid 30032640)
90. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and tgf-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99. (Pubitemid 44874293)
91. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990;10:1-10. (Pubitemid 20163701)
92. Haralson MA. Extracellular matrix and growth factors: an integrated interplay controlling tissue repair and progression to disease. Lab Invest 1993;69:369-72. (Pubitemid 23335836)
93. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000;6:391-407.
94. Badylak SF. The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol 2002;13:377-83. (Pubitemid 35300815)
95. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, et al. An oral endothelin-a receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000;118:1169-78. (Pubitemid 30346994)
96. Anselmi K, Subbotin VM, Nemoto E, Gandhi CR. Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist tak-044. J Gastroenterol Hepatol 2002;17:589-97. (Pubitemid 34748182)
97. Ali H, Dashwood M, Dawas K, Loizidou M, Savage F, Taylor I. Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharmacol 2000;36:S69-71.
98. Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, et al. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut 2004;53:1844-9. (Pubitemid 39556908)
99. Gandhi CR, Kuddus RH, Uemura T, Rao AS. Endothelin stimulates transforming growth factor-beta1 and collagen synthesis in stellate cells from control but not cirrhotic rat liver. Eur J Pharmacol 2000;406:311-8.
100. Ruetten H, Thiemermann C. Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone. J Physiol Pharmacol 1997;48:675-88. (Pubitemid 28055595)
101. Hafizi S, Allen SP, Goodwin AT, Chester AH, Yacoub MH. Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the et(a) receptor and is co-mitogenic with growth factors. Atherosclerosis 1999;146:351-9. (Pubitemid 29418067)
102. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 1999;21:759-75. (Pubitemid 29472503)
103. Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 2008;86:473-84.
104. Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-48. (Pubitemid 26043888)
105. Mallat A, Fouassier L, Preaux AM, Gal CS, Raufaste D, Rosenbaum J, et al. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic ito cells. An endothelin b receptor-mediated pathway. J Clin Invest 1995;96:42-9.
106. Mallat A, Fouassier L, Preaux AM, Mavier P, Lotersztajn S. Antiproliferative effects of et-1 in human liver ito cells: an etb- and a cyclic amp-mediated pathway. J Cardiovasc Pharmacol 1995;26(Suppl 3):S132-134.
107. Gallois C, Habib A, Tao J, Moulin S, Maclouf J, Mallat A, et al. Role of nf-kappab in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J Biol Chem 1998;273:23183-90. (Pubitemid 28417502)
108. Mallat A, Gallois C, Tao J, Habib A, Maclouf J, Mavier P, et al. Platelet-derived growth factor-bb and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic amp pathway and cross-talk with endothelin receptors. J Biol Chem 1998;273:27300-5. (Pubitemid 28500444)
109. Piacentini L, Gray M, Honbo NY, Chentoufi J, Bergman M, Karliner JS. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase c. J Mol Cell Cardiol 2000;32:565-76. (Pubitemid 30658926)
110. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
111. Edwards RM, Trizna W, Ohlstein EH. Renal microvascular effects of endothelin. Am J Physiol 1990;259:F217-221.
112. Bergler-Klein J, Pacher R, Berger R, Bojic A, Stanek B. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant 2004;23:20-7. (Pubitemid 38084826)
113. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary raynaud's phenomenon. Lancet 1990;336:1144-7. (Pubitemid 20362904)
114. Tripathi D, Therapondos G, Ferguson JW, Newby DE, Webb DJ, Hayes PC. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006;55:1290-5. (Pubitemid 44277360)
115. Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410-5. (Pubitemid 36250063)
116. Lavelle A, Sugrue R, Lawler G, Mulligan N, Kelleher B, Murphy DM, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009;34:770-1.
117. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-a receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8. (Pubitemid 34634407)
118. Clozel M. Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 2000;35:S65-68.
119. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 2002;1:986-1001. (Pubitemid 37361604)
120. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
121. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-19. (Pubitemid 351415492)
122. Casserly B, Klinger JR. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther 2009;2:265-80.
123. Shepard DR, Dreicer R. Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opin Investig Drugs 2010;19:899-908.
124. Wu-Wong JR. S-0139 (shionogi). Curr Opin Investig Drugs 2002;3:1051-6.